1. Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis 2021; 17: 365-70.
2.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-57.
3.
Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. JAMA 2020; 323: 1175-83. Erratum in: JAMA 2020; 323: 1619.
4.
Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842-5.
5.
Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-10.
6.
Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-5.
7.
Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
8.
Povero D, Eguchi A, Li H, et al. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One 2014; 9: e113651.
9.
Wang X, He Y, Mackowiak B, Gao B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut 2021; 70: 784-95.
10.
López-Pastor AR, Infante-Menéndez J, Escribano Ó, Gómez-Hernández A. miRNA dysregulation in the development of non-alcoholic fatty liver disease and the related disorders type 2 diabetes mellitus and cardiovascular disease. Front Med 2020; 7: 527059.
11.
Liang Q, Chen H, Xu X, Jiang W. miR-182-5p attenuates high-fat -diet-induced nonalcoholic steatohepatitis in mice. Ann Hepatol 2019; 18: 116-25.
12.
Compagnoni C, Capelli R, Zelli V, et al. MiR-182-5p is upregulated in hepatic tissues from a diet-induced NAFLD/NASH/HCC C57BL/6J mouse model and modulates Cyld and Foxo1 expression. Int J Mol Sci 2023; 24: 9239.
13.
Huan L, Bao C, Chen D, et al. MicroRNA-127-5p targets the biliverdin reductase B/nuclear factor-kB pathway to suppress cell growth in hepatocellular carcinoma cells. Cancer Sci 2016; 107: 258-66.
14.
Pan C, Chen H, Wang L, et al. Down-regulation of MiR-127 facilitates hepatocyte proliferation during rat liver regeneration. PLoS One 2012; 7: e39151.
15.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77: 1797-835.
16.
Solayman MH, Langaee T, Patel A, et al. Identification of suitable endogenous normalizers for qRT-PCR analysis of plasma microRNA expression in essential hypertension. Mol Biotechnol 2016; 58: 179-87.
17.
Abdelaleem OO, Mohammed SR, El Sayed HS, et al. Serum miR-34a-5p and miR-199a-3p as new biomarkers of neonatal sepsis. PLoS One 2022; 17: e0262339.
18.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
19.
Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
20.
Wang Z, Zhu S, Jia Y, et al. Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease. Cell 2023; 186: 1968-84.e20.
21.
Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol 2016; 231: 25-30.
22.
Kai K, Dittmar RL, Sen S. Secretory microRNAs as biomarkers of cancer. Semin Cell Dev Biol 2018; 78: 22-36.
23.
He Z, Hu C, Jia W. miRNAs in non-alcoholic fatty liver disease. Front Med 2016; 10: 389-96.
24.
Gholizadeh M, Szelag-Pieniek S, Post M, et al. Identifying differentially expressed microRNAs, target genes, and key pathways deregulated in patients with liver diseases. Int J Mol Sci 2020; 21: 7368.
25.
Tryndyak VP, Ross SA, Beland FA, Pogribny IP. Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol Carcinog 2009; 48: 479-87.
26.
Sommars MA, Ramachandran K, Senagolage MD, et al. Dynamic repression by BCL6 controls the genome-wide liver response to fasting and steatosis. Elife 2019; 8: e43922.
27.
Senagolage MD, Sommars MA, Ramachandran K, et al. Loss of transcriptional repression by BCL6 confers insulin sensitivity in the setting of obesity. Cell Rep 2018; 25: 3283-98.e6.
28.
Chikada H, Ida K, Nishikawa Y, et al. Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice. Sci Rep 2020; 10: 9704.
29.
Heida A, Gruben N, Catrysse L, et al. The hepatocyte IKK:NF-kB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis. Mol Metab 2021; 54: 101349.
30.
Zhou J, Lu S, Yang S, et al. MicroRNA-127 post-transcriptionally downregulates Sept7 and suppresses cell growth in hepatocellular carcinoma cells. Cell Physiol Biochem 2014; 33: 1537-46.
31.
Yang Z, Zhang Y, Wang L. A feedback inhibition between miRNA-127 and TGFb/c-Jun cascade in HCC cell migration via MMP13. PLoS One 2013; 8: e65256.
32.
Mendonsa AM, VanSaun MN, Ustione A, et al. Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver. Mol Cancer 2015; 14: 49.
33.
Zhang Y, Xiang D, Hu X, et al. Identification and study of differentially expressed miRNAs in aged MASLD rats based on high-throughput sequencing. Ann Hepatol 2020; 19: 302-12.
34.
Shoelson S, Lee J, Yuan M. Inflammation and the IKKb/IkB/NF-kB axis in obesity- and diet-induced insulin resistance. Int J Obes 2003; 27 (Suppl 3): S49-52.
35.
Melkman-Zehavi T, Oren R, Kredo-Russo S, et al. MiRNAs control insulin content in pancreatic b 2-cells via downregulation of transcriptional repressors. EMBO J 2011; 30: 835-45.
36.
Zhou J, Meng Y, Tian S, et al. Comparative microRNA expression profiles of cynomolgus monkeys, rat, and human reveal that mir-182 is involved in T2D pathogenic processes. J Diabetes Res 2014; 2014: 760397.
37.
Dong M, Ye Y, Chen Z, et al. MicroRNA 182 is a novel negative regulator of adipogenesis by targeting CCAAT/enhancer-binding protein a. Obesity 2020; 28: 1467-76.
38.
Tang X, Qin Q, Xu W, Zhang X. Long non-coding RNA TUG1 attenuates insulin resistance in mice with gestational diabetes mellitus via regulation of the microRNA-328-3p/SREBP-2/ERK axis. Diabetes Metab J 2023; 47: 267-86.
